Construction method and application of keratoconus diagnostic model

By screening and constructing a keraconus diagnostic model based on gene expression data, the problems of inconvenience in use and unknown pathogenesis of existing screening devices are solved, and the accuracy and prognosis of early keraconus screening are improved.

CN117936076BActive Publication Date: 2024-11-12PEKING UNION MEDICAL COLLEGE HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410130415.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-31
Publication Date
2024-11-12
Estimated Expiration
2044-01-31

AI Technical Summary

Technical Problem

The existing keratoconus screening devices are inconvenient to use, which leads to difficulty in early screening, and the pathogenesis of keratoconus is unknown, and there is a lack of effective therapeutic targets, which affects the prognosis of patients.

Method used

By obtaining corneal sample gene expression data of keratoconus patients and healthy controls, differential genes were screened, and an efficient diagnostic model was constructed. Efficient diagnostic genes such as EPS8, EPS8_NEB, NEB_RASSF2_EPS8, RASSF2_EPS8, FCGR2A_RASSF2_EPS8 were used for early screening, and combined with the results of tear sample sequencing AUC value, a diagnostic model is constructed to determine whether the patient is a keraconus patient.

Benefits of technology

It improves the accuracy and efficiency of early screening of keratoconus, improves the prognosis level of patients, and provides a more comprehensive analysis of corneal characteristics to help early detection and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117936076B_ABST
    Figure CN117936076B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine, and specifically relates to a method for constructing a keratoconus diagnostic model and its application. Specifically, the present invention provides a method for constructing an efficient diagnostic model for keratoconus, and the construction method comprises the following steps: 1) obtaining gene expression data obtained by testing a first group of corneal samples of keratoconus patients and healthy controls, and screening genes that differ in performance between keratoconus patients and healthy controls; 2) obtaining gene expression data obtained by testing a second group of corneal samples of keratoconus patients and healthy controls, and screening genes that differ in performance between keratoconus patients and healthy controls; 3) taking the intersection of the differential genes obtained in 1) and 2), combining the intersection genes or their constituent genes in the sequencing results of tear samples of keratoconus patients and healthy controls to calculate their diagnostic AUC values, wherein genes or gene groups with AUC>0.7 are combined as efficient diagnostic genes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to a construction method and application of a keratoconus diagnosis model. Background Art

[0002] Keratoconus, abbreviated as KC, KCN, and KTCN, is a common non-inflammatory, chronic, progressive, and localized corneal ectasia disease characterized by thinning of the central or paracentral corneal stroma, protrusion and deformation of the central vertex in a cone shape, loss of the normal curvature of the cornea, irregular astigmatism, and scar formation, which leads to a serious reduction in the optical performance of the cornea, just like a camera lens that is severely distorted and deformed, causing serious damage to vision. It often causes highly irregular myopic astigmatism, and in the late stage, acute corneal edema, scar formation, and a significant decrease in vision. Keratoconus is one of the important clinical blinding eye diseases, mostly occurring in young people and minors. The incidence rate is about 1 / 2000 (there are differences between different races) and is increasing year by year, affecting the patient's quality of life, productivity, and career choice. 10% to 20% of severe cone patients require corneal transplantation, but the source of corneal donors in my country is tight, and patients and society are under great pressure.

[0003] Currently, doctors use screening devices to perform early screening for adolescent keratoconus eye diseases in order to detect and treat them early. However, existing screening devices are generally installed in a fixed manner, which makes it inconvenient for doctors to adjust the use position of the screening device, resulting in reduced practicality of the screening device, and thus inconvenient for doctors to screen for keratoconus eye diseases through the screening device. At the same time, mid- and late-stage keratoconus cases are easier to diagnose, and it is more challenging to detect early keratoconus patients. Because the initial manifestations of keratoconus are not obvious, a more comprehensive analysis of corneal characteristics is required.

[0004] The pathological mechanism of keratoconus is still unclear, and there is currently no therapeutic target closely related to the pathogenesis of the disease. The pathogenesis of keratoconus is quite complex, and there is no recognized, systematic theory to explain the occurrence and development of the disease. Related research has mostly focused on genetic factors, corneal biomechanics, and oxidative stress. In families with early onset, severe disease, dominant or recessive inheritance, genetic factors may account for almost all risks. In the past, it was believed that genetic genes, such as hepatocyte growth factor (HGF), visual system homebox1 (VSX1), and zinc finger protein 469 (ZNF469), play an important role in the pathogenesis of keratoconus, and more and more other genes have been found to be closely related to it.

[0005] It is of great significance to develop new methods for early screening of keratoconus and improve the prognosis of keratoconus. Summary of the invention

[0006] In order to effectively screen keratoconus at an early stage and improve the prognosis of keratoconus patients, the present invention provides the following technical solutions:

[0007] In a first aspect, the present invention provides a method for constructing an efficient diagnostic model for keratoconus, the method comprising the following steps:

[0008] 1) Obtain gene expression data obtained by testing a first group of corneal samples from patients with keratoconus and healthy controls, and screen genes with differential expression between patients with keratoconus and healthy controls;

[0009] 2) obtaining gene expression data from a second set of corneal samples from patients with keratoconus and healthy controls, and screening for genes that express differently between patients with keratoconus and healthy controls;

[0010] 3) Taking the intersection of the differentially expressed genes obtained in 1) and 2), calculating the diagnostic AUC value of the intersection genes or their gene combinations in the sequencing results of tear samples of keratoconus patients and healthy controls, wherein the genes or gene combinations with AUC>0.7 are regarded as efficient diagnostic genes;

[0011] 4) Using the highly efficient diagnostic gene to construct a highly efficient diagnostic model for keratoconus.

[0012] Preferably, the intersection genes have the same change trend in the samples of step 1), 2) or 3).

[0013] Preferably, the corneal sample can be selected from GSE77938 and GSE151631.

[0014] Preferably, the tear samples of the keratoconus patients and healthy controls are obtained from clinics.

[0015] Preferably, the highly efficient diagnostic gene is EPS8.

[0016] Preferably, the highly efficient diagnostic gene is EPS8_NEB.

[0017] Preferably, the highly efficient diagnostic gene is NEB_RASSF2_EPS8.

[0018] Preferably, the highly efficient diagnostic gene is RASSF2_EPS8.

[0019] Preferably, the highly efficient diagnostic gene is FCGR2A_RASSF2_EPS8.

[0020] Preferably, the highly efficient diagnostic gene can be applied to the detection of subject samples including but not limited to cornea (corneal tissue) and tears, and whether the subject is a keratoconus patient can be determined based on the test results. Other samples can also be any biological sample separated from the subject, for example, whole blood, platelets, serum, plasma, red blood cells, white blood cells or leukocytes, endothelial cells, tissue biopsy, synovial fluid, lymphatic fluid, ascites, interstitial or extracellular fluid, fluid in the intercellular space, including gingival sulcus fluid, bone marrow, cerebrospinal fluid, saliva, mucus, sputum, semen, sweat, urine, nasal brush fluid, Pap smear fluid or any other body fluid. Body fluids can include saliva, blood or serum.

[0021] In one aspect, the present invention provides an efficient diagnostic model device for keratoconus, the device comprising: a memory and a processor;

[0022] The memory is used to store program instructions;

[0023] The processor is used to call program instructions, and when the program instructions are executed, it is used to perform the following operations:

[0024] Obtain gene expression data of the highly efficient diagnostic gene of the sample to be tested, input the gene expression data into a keratoconus diagnostic model constructed by the highly efficient diagnostic gene, and obtain a diagnostic result of the sample to be tested; the highly efficient diagnostic gene is selected from any one of the following:

[0025] 1) EPS8,

[0026] 2) EPS8_NEB,

[0027] 3)NEB_RASSF2_EPS8,

[0028] 4) RASSF2_EPS8,

[0029] 5)FCGR2A_RASSF2_EPS8.

[0030] Preferably, the sample to be tested is cornea and / or tear fluid.

[0031] In one aspect, the present invention provides a diagnostic system for keratoconus, comprising:

[0032] An acquisition unit, used for acquiring gene expression data of a highly effective diagnostic gene of a sample to be tested;

[0033] A processing unit, inputting the gene expression data into a keratoconus diagnosis model constructed by high-efficiency diagnostic genes to obtain a diagnosis result of the sample to be tested;

[0034] The highly efficient diagnostic gene is selected from any one of the following:

[0035] 1) EPS8,

[0036] 2) EPS8_NEB,

[0037] 3)NEB_RASSF2_EPS8,

[0038] 4) RASSF2_EPS8,

[0039] 5)FCGR2A_RASSF2_EPS8.

[0040] Preferably, the sample to be tested is cornea and / or tear fluid.

[0041] In one aspect, the present invention provides a computer-readable storage medium having a computer program stored thereon, wherein when the computer program is executed by a processor, the following method is implemented:

[0042] Obtain gene expression data of the highly efficient diagnostic gene of the sample to be tested, input the gene expression data into a keratoconus diagnostic model constructed by the highly efficient diagnostic gene, and obtain a diagnostic result of the sample to be tested; the highly efficient diagnostic gene is selected from any one of the following:

[0043] 1) EPS8,

[0044] 2) EPS8_NEB,

[0045] 3)NEB_RASSF2_EPS8,

[0046] 4) RASSF2_EPS8,

[0047] 5)FCGR2A_RASSF2_EPS8.

[0048] In one aspect, the present invention provides the use of a reagent for detecting the expression level of a high-efficiency diagnostic gene combination in the preparation of a product for diagnosing keratoconus, wherein the high-efficiency diagnostic gene is selected from any one of the following:

[0049] 1) EPS8,

[0050] 2) EPS8_NEB,

[0051] 3)NEB_RASSF2_EPS8,

[0052] 4) RASSF2_EPS8,

[0053] 5)FCGR2A_RASSF2_EPS8.

[0054] Preferably, the reagents for detecting the protein expression amount include reagents used in the following methods: hematoxylin-eosin staining, safranin O-fast green staining, protein blotting, enzyme-linked immunosorbent assay, radioimmunoassay, sandwich assay, immunohistochemical staining method, mass spectrometry, immunoprecipitation analysis, complement fixation analysis, flow cytometry fluorescence resolution technology and protein chip method;

[0055] Preferably, the reagents for detecting the mRNA expression amount include reagents used in the following methods: detection method based on PCR principle, Southern hybridization method, Northern hybridization method, dot hybridization method, fluorescence in situ hybridization method, DNA microarray method, ASO method, high-throughput sequencing platform method. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 It is a schematic flow chart of constructing an efficient keratoconus diagnosis model provided by an embodiment of the present invention.

[0057] Figure 2 These are the results of differential expression analysis of EPS8 in GSE77938, GSE151631 and clinical samples.

[0058] Figure 3 The figure is a diagnostic ROC curve diagram of the efficient diagnostic gene provided by the present invention when EPS8 is used as the efficient diagnostic gene.

[0059] Figure 4 These are the results of differential expression analysis by NEB in GSE77938, GSE151631 and clinical samples.

[0060] Figure 5 These are the results of differential expression analysis of RASSF2 in GSE77938, GSE151631 and clinical samples. Figure 6 The diagnostic ROC curve diagram of the efficient diagnostic gene provided by the present invention when EPS8_NEB is used as the efficient diagnostic gene.

[0061] Figure 7 The diagnostic ROC curve diagram of the efficient diagnostic gene provided by the present invention is when NEB_RASSF2_EPS8 is used as the efficient diagnostic gene.

[0062] Figure 8 These are the results of differential expression analysis of FCGR2A in GSE77938, GSE151631 and clinical samples. Fig. 9 The diagnostic ROC curve diagram of the efficient diagnostic gene provided by the present invention is when RASSF2_EPS8 is used as the efficient diagnostic gene.

[0063] Fig.10The diagnostic ROC curve diagram of the efficient diagnostic gene provided by the present invention is when FCGR2A_RASSF2_EPS8 is used as the efficient diagnostic gene.

[0064] Fig.11 It is clinical information of patients with keratoconus.

[0065] Fig.12 It is the clinical information of healthy controls. DETAILED DESCRIPTION

[0066] The present invention is further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes based on the technical solution and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.

[0067] Unless otherwise specified, the materials and reagents used in the following examples can be obtained from commercial sources.

[0068] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.

[0069] In some of the processes described in the specification and claims of the present invention and the above-mentioned figures, multiple operations that appear in a specific order are included, but it should be clearly understood that these operations may not be executed in the order in which they appear in this article or executed in parallel. The serial numbers of the operations, such as 101, 102, etc., are only used to distinguish different operations, and the serial numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel. It should be noted that the descriptions of "first", "second", etc. in this article are used to distinguish different messages, devices, modules, etc., do not represent the order of precedence, and do not limit the "first" and "second" to be different types.

[0070] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.

[0071] Figure 1 The present invention provides a schematic flow chart of constructing an efficient diagnosis model for keratoconus. Specifically, the method comprises the following steps:

[0072] 1) Obtain gene expression data obtained by testing a first group of corneal samples from patients with keratoconus and healthy controls, and screen genes with differential expression between patients with keratoconus and healthy controls;

[0073] 2) obtaining gene expression data from a second set of corneal samples from patients with keratoconus and healthy controls, and screening for genes that express differently between patients with keratoconus and healthy controls;

[0074] 3) Taking the intersection of the differentially expressed genes obtained in 1) and 2), calculating the diagnostic AUC value of the intersection genes or their gene combinations in the sequencing results of tear samples of keratoconus patients and healthy controls, wherein the genes or gene combinations with AUC>0.7 are regarded as efficient diagnostic genes;

[0075] 4) Using the highly efficient diagnostic gene to construct a highly efficient diagnostic model for keratoconus.

[0076] Preferably, the intersection genes have the same change trend in the samples of step 1), 2) or 3).

[0077] In one embodiment, step 101 is to download the expression matrix of GSE77938 data (corneal samples, transcriptome sequencing) from GEO, the data includes two parts: discovery (Control: keratoconus = 8:8) and replication (Control: keratoconus = 17:17), and use the sva package of R language to de-batch the two parts of data to obtain the analysis data set, and then use the limma package to perform differential expression analysis, the screening criteria are: Pvalue <0.05 & |logFC|>0.5, and 1578 differentially expressed genes are obtained, of which 464 are up-regulated and 1114 are down-regulated.

[0078] In one embodiment, step 102 is to download the count matrix of GSE151631 data (corneal samples, transcriptome sequencing) from GEO, the data includes Control: keratoconus = 7: 19, and perform differential expression analysis using the DESeq2 package of R language, the screening criteria are: Pvalue < 0.05 & |logFC| > 1, and obtain 4044 differentially expressed genes, of which 1321 are upregulated and 2723 are downregulated.

[0079] In one embodiment, step 103 is to collect tear samples from keratoconus patients and healthy controls for proteomic sequencing, and calculate the AUC of the intersection gene or its gene combination in diagnosing keratoconus according to the protein sequencing results, wherein the gene or gene combination with AUC>0.7 is regarded as a highly effective diagnostic gene. The sample information of the keratoconus patients and healthy controls is as follows: Figure 11-12 shown.

[0080] In one embodiment, the highly effective diagnostic gene obtained in step 103 is EPS8, and the expression level of EPS8 is downregulated in corneal samples and tear samples of patients with keratoconus ( Figure 2 ), the AUC value calculated in tear samples of keratoconus patients and healthy controls was 0.762 ( Figure 3 ).

[0081] In one embodiment, the intersection genes screened in step 103 are EPS8, NEB and RASSF2, and the efficient diagnostic gene whose AUC value is calculated and screened to reach 0.7 is EPS8_NEB or NEB_RASSF2_EPS8, and the expression level of EPS8 is downregulated in the corneal samples and tear samples of patients with keratoconus ( Figure 2 ), the NEB was down-regulated in corneal samples and tear samples of patients with keratoconus ( Figure 4 ), the expression of RASSF2 was downregulated in both corneal samples and tear samples of patients with keratoconus ( Figure 5 ), the AUC value of EPS8_NEB calculated in tear samples of keratoconus patients and healthy controls was 0.746 ( Figure 6 ), the AUC value of NEB_RASSF2_EPS8 calculated in tear samples of keratoconus patients and healthy controls was 0.741 ( Figure 7 In the figure, the AUC value of 0.501 is the value when NEB is used alone as the diagnostic gene, 0.655 is the value when RASSF2 is used alone as the diagnostic gene, and 0.762 is the value when EPS8 is used alone as the diagnostic gene).

[0082] In one embodiment, the intersection genes screened in step 103 are EPS8, FCGR2A and RASSF2, and the efficient diagnostic gene whose AUC value is calculated and screened to reach 0.7 is RASSF2_EPS8 or FCGR2A_RASSF2_EPS8, and the expression level of EPS8 is downregulated in corneal samples and tear samples of patients with keratoconus ( Figure 2 ), the expression of FCGR2A was downregulated in both corneal samples and tear samples of patients with keratoconus ( Figure 8 ), the expression of RASSF2 was downregulated in both corneal samples and tear samples of patients with keratoconus ( Figure 5 ), the AUC value of RASSF2_EPS8 calculated in tear samples of keratoconus patients and healthy controls was 0.753 ( Fig. 9 ), the AUC value of FCGR2A_RASSF2_EPS8 calculated in tear samples of keratoconus patients and healthy controls was 0.751 ( Fig.10 In the figure, the AUC value of 0.587 is the value when FCGR2A is used alone as the diagnostic gene, 0.655 is the value when RASSF2 is used alone as the diagnostic gene, and 0.762 is the value when EPS8 is used alone as the diagnostic gene).

[0083] Specifically, in the present invention, the names of multiple genes connected by "_" are used to represent a combination of multiple markers. For example, RASSF2_EPS8 refers to a combination of RASSF2 and EPS8, which are used simultaneously.

[0084] In one embodiment, the efficient diagnostic model may include but is not limited to classification and logistic regression (Logistic Regression) model, k-nearest neighbor (kNN) model, Naive Bayes (NB) model, Support Vector Machine (SVM), Decision Tree (DT) model, Random Forests (RF) model, Regression Tree (CART) model, Gradient Boosting Decision Tree (GBDT) model, xgboost (eXtreme Gradient Boosting), Light Gradient Boosting Machine (LightGBM), Gradient Boosting Machines (GBM), LASSO (Least Absolute Shrinkage and Selection Operator, LASSO), Convolutional Neural Networks (CNN), etc.

[0085] As described in the present invention, the gene expression data may be data on mRNA or protein expression levels and may be derived from any sample, so that corresponding diagnostic markers can be screened.

[0086] As stated in the present invention, "down-regulated expression" refers to the changing trend of the expression level of the molecular marker in the keratoconus sample relative to that of the non-patient (control), for example, about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% of the non-patient, and the non-patient refers to a subject who does not suffer from Sjögren's syndrome.

[0087] In order to evaluate the effectiveness of the diagnostic model of the present invention, the AUC area of ​​the ROC calculation model is used; the ROC curve is a chart showing the effect of the classification model under all classification thresholds. The curve plots the following two parameters: true positive rate and false positive rate. The area under the curve is called AUC (Area Under Curve), which is used to indicate the prediction accuracy. The higher the AUC value, that is, the larger the area under the curve, the higher the prediction accuracy.

[0088] The term "diagnosis" as used herein refers to the discovery, judgment or recognition of an individual's health status or condition based on one or more symptoms, data or other information related to the individual. An individual's health status may be diagnosed as healthy / normal (i.e., the absence of a disease or illness), or may be diagnosed as unhealthy / abnormal (i.e., the presence of a disease or illness), and the term "diagnosis" includes the early discovery of a disease related to the disease; the characteristics or classification of the disease; the discovery of the progression, cure or recurrence of the disease; and the discovery of an individual's response to the disease after treatment or treatment.

[0089] The validation results of this validation example show that assigning intrinsic weights to indications can moderately improve the performance of the method relative to the default setting.

[0090] Those skilled in the art can clearly understand that, for the convenience and brevity of description, the specific working processes of the systems, devices and units described above can refer to the corresponding processes in the aforementioned method embodiments and will not be repeated here.

[0091] In the several embodiments provided in the present application, it should be understood that the disclosed systems, devices and methods can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the units is only a logical function division. There may be other division methods in actual implementation, such as multiple units or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or units, which can be electrical, mechanical or other forms.

[0092] The units described as separate components may or may not be physically separated, and the components shown as units may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.

[0093] In addition, each functional unit in each embodiment of the present invention may be integrated into one processing unit, or each unit may exist physically separately, or two or more units may be integrated into one unit. The above-mentioned integrated unit may be implemented in the form of hardware or in the form of software functional units.

[0094] Machine-readable storage media may include data storage materials encoded with machine-readable data or data arrays that can be used for a variety of purposes when a machine programmed with instructions for using the data is used. The measurement of effective amounts of the biomarkers of the present invention and / or the risk assessment derived from those biomarkers can be implemented in a computer program executed on a programmable computer, the computer including, among other things, a processor, a data storage system (including volatile and non-volatile memory and / or storage elements), at least one input device, and at least one output device. The program code can be applied to the input data to perform the functions described above and generate output information. The output information can be applied to one or more output devices according to methods known in the art. The computer can be, for example, a personal computer, a microcomputer, or a workstation of conventional design. Each program can be implemented in a high-level procedural or object-oriented programming language to communicate with the computer system. However, if desired, the program can be implemented in assembly language or machine language. The language can be a compiled or interpreted language. Each such computer program can be stored on a storage medium or device (e.g., a ROM or disk or other defined elsewhere in the present disclosure) that can be read by a general or special purpose programmable computer for configuring and operating the computer to perform the processes described herein when the storage medium or device is read by the computer. The health-related data management system used in some aspects of the present invention may also be considered to be implemented as a computer-readable storage medium configured with a computer program, where the storage medium so configured causes a computer to operate in a specific and predetermined manner to perform the various functions described herein.

Claims

1. A method for constructing an efficient diagnostic model for keratoconus, the method comprising the following steps: 1) Obtain gene expression data from the first group of corneal samples from patients with keratoconus and healthy controls, and screen for genes that express differences between patients with keratoconus and healthy controls; 2) Obtain gene expression data from a second set of corneal samples from patients with keratoconus and healthy controls, and screen for genes that differ in expression between patients with keratoconus and healthy controls; 3) Take the intersection of the differentially expressed genes obtained in 1) and 2), and calculate the diagnostic AUC value of the intersection genes in the sequencing results of tear samples of keratoconus patients and healthy controls, among which the genes or gene combinations with AUC>0.7 are highly effective diagnostic genes; 4) Using the highly efficient diagnostic gene to construct a highly efficient diagnostic model for keratoconus; The highly efficient diagnostic gene is EPS8.

2. An efficient diagnostic model device for keratoconus, the device comprising: Memory and processor; The memory is used to store program instructions; The processor is used to call program instructions, and when the program instructions are executed, it is used to perform the following operations: Acquiring gene expression data of the highly efficient diagnostic gene of the sample to be tested, inputting the gene expression data into a keratoconus diagnostic model constructed by the highly efficient diagnostic gene, and obtaining a diagnostic result of the sample to be tested; The highly efficient diagnostic gene is EPS8.

3. A keratoconus diagnosis system, comprising: An acquisition unit, used for acquiring gene expression data of a highly effective diagnostic gene of a sample to be tested; A processing unit, inputting the gene expression data into a keratoconus diagnosis model constructed by high-efficiency diagnostic genes to obtain a diagnosis result of the sample to be tested; The highly efficient diagnostic gene is EPS8.

4. The diagnostic system according to claim 3, wherein the sample to be tested is cornea and / or tear fluid.

5. A computer-readable storage medium having a computer program stored thereon, wherein when the computer program is executed by a processor, the following method is implemented: Acquiring gene expression data of the highly efficient diagnostic gene of the sample to be tested, inputting the gene expression data into a keratoconus diagnostic model constructed by the highly efficient diagnostic gene, and obtaining a diagnostic result of the sample to be tested; The highly efficient diagnostic gene is EPS8.

6. Use of a reagent for detecting the expression level of a high-efficiency diagnostic gene combination in the preparation of a product for diagnosing keratoconus, wherein the high-efficiency diagnostic gene is EPS8.

7. The use according to claim 6, wherein the reagents for detecting the protein expression amount of the efficient diagnostic gene include reagents used in the following methods: hematoxylin-eosin staining, safranin O-fast green staining, protein blotting, enzyme-linked immunosorbent assay, radioimmunoassay, immunohistochemical staining method, mass spectrometry, immunoprecipitation analysis, complement fixation analysis, flow cytometry fluorescence resolution technology and protein chip method.

8. The use according to claim 6, wherein the reagents for detecting the mRNA expression level of the efficient diagnostic gene include reagents used in the following methods: a detection method based on the PCR principle, a Southern hybridization method, a Northern hybridization method, a dot hybridization method, a fluorescence in situ hybridization method, a DNA microarray method, an ASO method, and a high-throughput sequencing platform method.

9. A method for constructing an efficient diagnosis model for keratoconus, the method comprising the following steps: 1) Obtain gene expression data from the first group of corneal samples from patients with keratoconus and healthy controls, and screen for genes that express differences between patients with keratoconus and healthy controls; 2) Obtain gene expression data from a second set of corneal samples from patients with keratoconus and healthy controls, and screen for genes that differ in expression between patients with keratoconus and healthy controls; 3) Take the intersection of the differentially expressed genes obtained in 1) and 2), and calculate the diagnostic AUC value of the gene combination of the intersection genes in the sequencing results of tear samples of keratoconus patients and healthy controls, where the genes or gene combinations with AUC>0.7 are highly effective diagnostic genes; 4) Using the highly efficient diagnostic gene to construct a highly efficient diagnostic model for keratoconus; The highly effective diagnostic gene is selected from any one of the following: 1) EPS8 and NEB, 2) NEB, RASSF2 and EPS8, 3) RASSF2 and EPS8, 4) FCGR2A, RASSF2 and EPS8.

10. An efficient diagnostic model device for keratoconus, the device comprising: Memory and processor; The memory is used to store program instructions; The processor is used to call program instructions, and when the program instructions are executed, it is used to perform the following operations: Obtain gene expression data of the highly efficient diagnostic gene of the sample to be tested, input the gene expression data into a keratoconus diagnostic model constructed by the highly efficient diagnostic gene, and obtain a diagnostic result of the sample to be tested; the highly efficient diagnostic gene is selected from any one of the following: 1) EPS8 and NEB, 2) NEB, RASSF2 and EPS8, 3) RASSF2 and EPS8, 4) FCGR2A, RASSF2 and EPS8.

11. The diagnostic model device according to claim 10, wherein the sample to be tested is cornea and / or tear fluid.

12. A keratoconus diagnosis system, comprising: An acquisition unit, used for acquiring gene expression data of a highly effective diagnostic gene of a sample to be tested; The processing unit inputs the gene expression data into a keratoconus diagnostic model constructed by highly efficient diagnostic genes to obtain a diagnostic result of the sample to be tested; the highly efficient diagnostic gene is selected from any one of the following: 1) EPS8 and NEB, 2) NEB, RASSF2 and EPS8, 3) RASSF2 and EPS8, 4) FCGR2A, RASSF2 and EPS8.

13. The diagnostic system according to claim 12, wherein the sample to be tested is cornea and / or tear fluid.

14. A computer-readable storage medium having a computer program stored thereon, wherein when the computer program is executed by a processor, the following method is implemented: Obtain gene expression data of the highly efficient diagnostic gene of the sample to be tested, input the gene expression data into a keratoconus diagnostic model constructed by the highly efficient diagnostic gene, and obtain a diagnostic result of the sample to be tested; the highly efficient diagnostic gene is selected from any one of the following: 1) EPS8 and NEB, 2) NEB, RASSF2 and EPS8, 3) RASSF2 and EPS8, 4) FCGR2A, RASSF2 and EPS8.

15. Use of a reagent for detecting the expression level of a combination of highly effective diagnostic genes in the preparation of a product for diagnosing keratoconus, wherein the highly effective diagnostic gene is selected from any one of the following: 1) EPS8 and NEB, 2) NEB, RASSF2 and EPS8, 3) RASSF2 and EPS8, 4) FCGR2A, RASSF2 and EPS8.

16. The use according to claim 15, wherein the reagents for detecting the protein expression amount of the high-efficiency diagnostic gene include reagents used in the following methods: hematoxylin-eosin staining, safranin O-fast green staining, protein blotting, enzyme-linked immunosorbent assay, radioimmunoassay, immunohistochemical staining method, mass spectrometry, immunoprecipitation analysis, complement fixation analysis, flow cytometry fluorescence resolution technology and protein chip method.

17. The use according to claim 15, wherein the reagents for detecting the mRNA expression level of the efficient diagnostic gene include reagents used in the following methods: a detection method based on the PCR principle, a Southern hybridization method, a Northern hybridization method, a dot hybridization method, a fluorescence in situ hybridization method, a DNA microarray method, an ASO method, and a high-throughput sequencing platform method.